Anderson F H
University Department of Geriatric Medicine, Southampton General Hospital, UK.
Int J Clin Pract. 1998 Apr-May;52(3):176-80.
Osteoporosis in men is a common cause of morbidity, mortality and health care expenditure throughout the Western world. Most cases are secondary to disease or to drug therapy, but in 30-45% of affected individuals no cause can be identified. Research into the factors underlying 'idiopathic' male osteoporosis is limited, but is gradually moving more patients into the 'secondary' category. Recently, attention has focused on interactions between sex hormones and bone: there is evidence that male bone requires both androgens and oestrogens for normal health. Many conditions predispose to osteoporosis in men: hypogonadism, alcohol abuse and the use of corticosteroids are the most frequently identified factors. Osteoporosis following organ transplantation attracts interest despite its relative rarity. Treatment for osteoporotic men is poorly researched and remains largely unsupported by experimental evidence, although clinical experience suggests a useful role for bisphosphonates, testosterone and perhaps fluorides. Symptom control and explanation remain the most important therapeutic interventions.
在整个西方世界，男性骨质疏松症是导致发病、死亡和医疗保健支出的常见原因。大多数病例继发于疾病或药物治疗，但在30%-45%的受影响个体中，病因无法确定。对“特发性”男性骨质疏松症潜在因素的研究有限，但正逐渐使更多患者归入“继发性”类别。最近，注意力集中在性激素与骨骼之间的相互作用上：有证据表明，男性骨骼正常健康需要雄激素和雌激素。许多情况易导致男性患骨质疏松症：性腺功能减退、酗酒和使用皮质类固醇是最常见的因素。尽管器官移植后发生的骨质疏松症相对罕见，但仍引起了关注。对骨质疏松男性的治疗研究不足，在很大程度上仍缺乏实验证据支持，不过临床经验表明双膦酸盐、睾酮或许还有氟化物能发挥有益作用。症状控制和解释仍然是最重要的治疗干预措施。
